KR102389934B1 - 카르복시아미도트리아졸 오로트산에 반응한 다중 신호화 경로에 대한 방법과 분자의 약역학 바이오마커 - Google Patents

카르복시아미도트리아졸 오로트산에 반응한 다중 신호화 경로에 대한 방법과 분자의 약역학 바이오마커 Download PDF

Info

Publication number
KR102389934B1
KR102389934B1 KR1020167002926A KR20167002926A KR102389934B1 KR 102389934 B1 KR102389934 B1 KR 102389934B1 KR 1020167002926 A KR1020167002926 A KR 1020167002926A KR 20167002926 A KR20167002926 A KR 20167002926A KR 102389934 B1 KR102389934 B1 KR 102389934B1
Authority
KR
South Korea
Prior art keywords
cto
signature
delete delete
pathway
response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167002926A
Other languages
English (en)
Korean (ko)
Other versions
KR20160030535A (ko
Inventor
라지다 에이. 카말리
Original Assignee
탁티칼 떼라페우틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 탁티칼 떼라페우틱스 인크. filed Critical 탁티칼 떼라페우틱스 인크.
Publication of KR20160030535A publication Critical patent/KR20160030535A/ko
Application granted granted Critical
Publication of KR102389934B1 publication Critical patent/KR102389934B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020167002926A 2013-08-02 2014-07-30 카르복시아미도트리아졸 오로트산에 반응한 다중 신호화 경로에 대한 방법과 분자의 약역학 바이오마커 Active KR102389934B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/957,720 2013-08-02
US13/957,720 US10378059B2 (en) 2013-08-02 2013-08-02 Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate
PCT/US2014/048905 WO2015017545A1 (en) 2013-08-02 2014-07-30 Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate

Publications (2)

Publication Number Publication Date
KR20160030535A KR20160030535A (ko) 2016-03-18
KR102389934B1 true KR102389934B1 (ko) 2022-04-21

Family

ID=52428197

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167002926A Active KR102389934B1 (ko) 2013-08-02 2014-07-30 카르복시아미도트리아졸 오로트산에 반응한 다중 신호화 경로에 대한 방법과 분자의 약역학 바이오마커

Country Status (9)

Country Link
US (1) US10378059B2 (https=)
EP (1) EP3027776B1 (https=)
JP (1) JP6913459B2 (https=)
KR (1) KR102389934B1 (https=)
CN (1) CN105531380B (https=)
AU (1) AU2014296212B2 (https=)
CA (1) CA2919690C (https=)
IL (1) IL243894B (https=)
WO (1) WO2015017545A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10882841B2 (en) 2016-03-01 2021-01-05 University Of Maryland, Baltimore Wnt signaling pathway inhibitors for treatments of disease
JP6889009B2 (ja) * 2017-04-13 2021-06-18 浜松ホトニクス株式会社 画像取得システム及び画像取得方法
US20220168276A1 (en) * 2020-08-05 2022-06-02 Tactical Therapeotics Inc. Mehods and Compositions for Treating SARS-CoV-2 Infection using Carboxyamidotriazole Orotate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120202760A1 (en) 2009-09-04 2012-08-09 Rashida A. Karmali Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69633566T2 (de) * 1995-07-21 2005-12-08 Savvipharm Inc. Orotatsalze von 5-amino- oder substituierten amino-1,2,3-triazolen zur behandlung von neoplasmen
US20030170720A1 (en) * 2001-01-23 2003-09-11 Van Der Kuyl Antoinette Cornelia Means and methods for treatment evaluation
US8137910B2 (en) 2002-05-03 2012-03-20 Duke University Method of regulating gene expression
US8450057B2 (en) 2006-08-14 2013-05-28 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
US7750018B2 (en) * 2006-12-06 2010-07-06 Tactical Therapeutics, Inc Use of carboxiamidotriazole (CAI) orotate in macular degeneration
JP2010522567A (ja) 2007-03-28 2010-07-08 メダレックス インコーポレーティッド 遺伝子増幅および発現の方法
WO2009120561A2 (en) * 2008-03-22 2009-10-01 Merck & Co., Inc. Methods and gene expression signature for assessing growth factor signaling pathway regulation status
NZ598482A (en) * 2009-09-04 2014-05-30 Tactical Therapeutics Inc Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
WO2012135845A1 (en) * 2011-04-01 2012-10-04 Qiagen Gene expression signature for wnt/b-catenin signaling pathway and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120202760A1 (en) 2009-09-04 2012-08-09 Rashida A. Karmali Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate

Also Published As

Publication number Publication date
EP3027776A4 (en) 2017-03-08
CA2919690C (en) 2021-11-02
EP3027776C0 (en) 2024-02-07
JP6913459B2 (ja) 2021-08-04
WO2015017545A1 (en) 2015-02-05
US20150038349A1 (en) 2015-02-05
EP3027776A1 (en) 2016-06-08
AU2014296212B2 (en) 2020-10-22
IL243894B (en) 2020-06-30
US10378059B2 (en) 2019-08-13
JP2016526908A (ja) 2016-09-08
HK1220493A1 (en) 2017-05-05
IL243894A0 (en) 2016-04-21
CN105531380B (zh) 2021-07-13
CA2919690A1 (en) 2015-02-05
EP3027776B1 (en) 2024-02-07
CN105531380A (zh) 2016-04-27
AU2014296212A1 (en) 2016-02-25
KR20160030535A (ko) 2016-03-18

Similar Documents

Publication Publication Date Title
Fuentes-Fayos et al. Splicing machinery dysregulation drives glioblastoma development/aggressiveness: oncogenic role of SRSF3
Collins et al. PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment
Kobialka et al. The onset of PI3K‐related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib
Paccez et al. Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of Axl
Cai et al. Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour microenvironment in lower-grade glioma
Rubio et al. Non-canonical integrin signaling activates EGFR and RAS-MAPK-ERK signaling in small cell lung cancer
Skowron et al. Genetic and molecular alterations across medulloblastoma subgroups
Schulze et al. RELN signaling modulates glioblastoma growth and substrate‐dependent migration
Li et al. Paired related homeobox 1 transactivates dopamine D2 receptor to maintain propagation and tumorigenicity of glioma-initiating cells
Feng et al. Identification of a novel nomogram to predict progression based on the circadian clock and insights into the tumor immune microenvironment in prostate cancer
Gordian et al. Transforming growth factor β-induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer
Lee et al. CD133 regulates IL-1β signaling and neutrophil recruitment in glioblastoma
Lu et al. Combined targeting of glioblastoma stem cells of different cellular states disrupts malignant progression
Mat et al. Silencing of PROS1 induces apoptosis and inhibits migration and invasion of glioblastoma multiforme cells
Ji et al. HTRA3 is a prognostic biomarker and associated with immune infiltrates in gastric cancer
Fiala et al. Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation
Zhu et al. CDKN2A deletion in melanoma excludes T cell infiltration by repressing chemokine expression in a cell cycle-dependent manner
Lin et al. Identification of a 6-RBP gene signature for a comprehensive analysis of glioma and ischemic stroke: cognitive impairment and aging-related hypoxic stress
Zhong et al. FUCA2 is a prognostic biomarker and correlated with an immunosuppressive microenvironment in pan-cancer
Tabrizian et al. ASCL1 is activated downstream of the ROR2/CREB signaling pathway to support lineage plasticity in prostate cancer
Li et al. BPTF drives gastric cancer resistance to EGFR inhibitor by epigenetically regulating the C‐MYC/PLCG1/Perk Axis
Yuan et al. EGFRvIII-positive glioblastoma contributes to immune escape and malignant progression via the c-Fos-MDK-LRP1 axis
Zhang et al. A 63 signature genes prediction system is effective for glioblastoma prognosis
Johnson et al. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma
Grassi et al. The WNT pathway is relevant for the BCR-ABL1-independent resistance in chronic myeloid leukemia

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160202

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190726

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200622

Patent event code: PE09021S01D

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201215

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210627

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20201215

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20200622

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20210627

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210215

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200821

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20190726

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20210719

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20210707

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210627

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20210215

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200821

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190726

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220419

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220419

End annual number: 3

Start annual number: 1

PG1601 Publication of registration